文献速递耳科与耳神经

AM-101鼓室内重复给药治疗急性内耳耳鸣的安全性

Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus.
PubMed 文献 · Otolaryngol Head Neck Surg · 2017-06-13

这项前瞻性、双盲、随机、安慰剂对照研究在343例创伤性耳蜗损伤或中耳炎后持续性急性耳鸣患者中,评估3至5天内3次鼓室内注射AM-101 0.87 mg/mL或安慰剂的安全性,随访84天。主要安全终点为从基线至第35天有临床意义听力下降的发生率,结果显示治疗耐受良好,无干预相关严重不良事件,听力下降发生率低且两组相当(P = .82)。

要点

  • 3至5天内重复鼓室内注射AM-101耐受良好,无干预相关严重不良事件。
  • 主要安全终点听力下降发生率低,AM-101组与安慰剂组相当(P = .82)。
  • 92%受试者鼓膜在1周内闭合,至第84天全部闭合。

核心结论

  • 3至5天内重复鼓室内注射AM-101似乎安全且耐受良好,表明该给药方式可能可用于更长时间段。

主要发现

  • 治疗耐受良好,无干预相关严重不良事件。
  • 从基线至第35天有临床意义听力下降的发生率低,治疗组间相当(主要安全终点P = .82),单侧治疗受试者中治疗耳与未治疗耳间无差异。
  • 治疗和操作相关不良事件发生率在各治疗组间相似。
  • 92%受试者鼓膜在1周内闭合,至第84天全部受试者鼓膜闭合;血液指标和生命体征未见异常。

临床怎么用

  • 重复鼓室内注射AM-101在3至5天给药方案下表现出安全性和耐受性,支持该给药方式可能用于更长时间段。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To evaluate the safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor antagonist AM-101 in acute patients with inner ear tinnitus. Study Design Prospective, double-blind, randomized, placebo-controlled study. Setting Sixty-nine secondary and tertiary sites in North America, Europe, and Asia. Subjects and Methods In total, 343 subjects with persistent acute tinnitus after traumatic cochlear injury or otitis media were randomized to receive 3 intratympanic doses of either AM-101 0.87 mg/mL or placebo over 3 to 5 days. They were followed for 84 days. The primary safety end point was the incidence of a clinically meaningful hearing deterioration from baseline to study day 35. Further safety assessments included tympanic membrane closure rates, analysis of adverse events, hematology, blood chemistry, and vital signs. In addition, data were collected on applied anesthetics and injection techniques. Results The treatment was well tolerated, with no intervention-related serious adverse events. The incidence of clinically meaningful hearing deterioration was low, comparable between treatment groups ( P = .82 for the primary safety end point) and not different between treated and untreated ears in unilaterally treated subjects. The rate of treatment and procedure-related adverse events was similar among treatment groups. The tympanic membrane was closed in 92% of subjects within 1 week and in all subjects by study day 84. Blood values and vital signs were inconspicuous. Conclusion Repeated intratympanic injections of AM-101 over a 3- to 5-day period appear to be safe and well tolerated, demonstrating the ability to potentially use this delivery approach over longer time periods.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Staecker H, Morelock M, Kramer T, et al. Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus. Otolaryngol Head Neck Surg. 2017. PMID: 28608739. doi:10.1177/0194599817711378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。